ONCBeiGeneRunning, no new patients
A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.
Urothelial Carcinoma · Renal Cell Carcinoma · Melanoma · Non-mucosal Melanoma
12Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due May 2025, none posted yet
Counts until it's fixed
- +1.7
2 insiders sold shares within a month
Since Aug 3, 2026 · was worth 5, fading over time
Worry score12
Score over time
- Stage
- Phase 1/2
- Patients
- 113 (final count)
- Started
- Jan 9, 2023
- Main results expected
- May 27, 2025
- Fully finished
- Oct 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Response Rate (ORR) as Assessed by the Investigator
Measured over: Up to approximately 26 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-05-27, no fading
- insider_selling_cluster: base 5, now 1.7, since 2026-08-03, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05661955 · record last updated 2026-05-11 · checked 2026-11-09 15:47 UTC